Format

Send to

Choose Destination
Am J Cardiol. 2017 Jul 15;120(2):213-217. doi: 10.1016/j.amjcard.2017.04.009. Epub 2017 Apr 27.

Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.

Author information

1
Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
2
Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
3
Quality and Safety, Memorial Sloan Kettering Cancer Center, New York, New York.
4
Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York.
5
Pharmacy Department, Memorial Sloan Kettering Cancer Center, New York, New York.
6
Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: manthas@mskcc.org.

Abstract

Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with nonvalvular atrial fibrillation (AF). However, there is little published evidence on the safety and efficacy of rivaroxaban for AF in patients with active cancer. The aim of this study was to assess the safety and efficacy of rivaroxaban in patients with active cancer and AF. The use of rivaroxaban in patients with cancer at the Memorial Sloan Kettering Cancer Center is monitored in the setting of a Quality Assessment Initiative. Patients with active cancer and AF, treated with rivaroxaban from January 1, 2014, to March 31, 2016, are included in this analysis. Clinical end points were defined a priori and assessed through text searches of medical records. A total of 163 evaluable patients were identified. After adjusting for competing risks, the estimated 1-year cumulative incidence of ischemic stroke was 1.4% (95% CI 0% to 3.4%) and major bleeding was 1.2% (95% CI 0% to 2.9%). The risk of clinically relevant nonmajor bleeding leading to discontinuation of anticoagulation at 1 year was 14.0% (95% CI 4.2% to 22.7%). The cumulative incidence of mortality was 22.6% (95% CI 12.2% to 31.7%) at 1 year, reflecting an active cancer population. One patient died after developing an acute ischemic cerebrovascular insult. In conclusion, the safety and efficacy of rivaroxaban treatment for nonvalvular AF in patients with active cancer is comparable to the results of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) study in the general population.

PMID:
28549819
PMCID:
PMC5523442
DOI:
10.1016/j.amjcard.2017.04.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center